 | | Vol. 16.19 – 16 May, 2024 |
| |
|
|
| Using a mouse mammary gland model, investigators delved into the regulatory role of sympathetic nervous signaling in the context of mammary stem cells and mammary development.
[Journal Of Molecular Cell Biology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers identified Resf1 as a novel metastasis susceptibility gene in ER- breast cancer. Reduction of Resf1 resulted in a significant increase in tumor growth, a shortened overall survival time, and increased incidence and number of lung metastases, consistent with patient data.
[PLOS Genetics] |
|
|
|
| The authors established MCF-10A cell lines incubated with TNF-α to investigate the effects of continuous TNF-α exposure on the phenotypic change of normal mammary epithelial cells.
[Archives Of Pharmacal Research] |
|
|
|
| Scientists reported that phosphoglycerate mutase 1 suppression in breast cancer cells led to a decrease in M2 polarization, migration, and interleukin-10 production of macrophages.
[Cancer Gene Therapy] |
|
|
|
| Researchers elucidated the role of WDR61 in breast tumor development, and reported that knockdown of WDR61 compromised the proliferation of breast tumor cells with reduced colony-forming capacity.
[FEBS Journal] |
|
|
|
| Scientists loaded vincristine sulfate (VCR) on exosomes generated from mesenchymal stem cells (MSCs) to enhance its targeted distribution, and reported that loading VCR sulfate to MSCs-derived exosomes could improve their targeted delivery and lessen their side effects.
[Scientific Reports] |
|
|
|
|
| The authors provide a comprehensive review on the clinical features, molecular characteristics, invasion and metastasis patterns, and prognosis of metaplastic breast cancer, as well as recent advancements in treatment strategies.
[Cancer Science] |
|
|
|
|
| Intensity Therapeutics, Inc. announced that they executed a collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase II randomized, controlled trial evaluating clinical and biological effects of intratumoral INT230-6 in early-stage triple-negative breast cancer.
[Intensity Therapeutics, Inc.] |
|
|
|
|
| June 19-20, 2024
Toronto, Ontario, Canada |
|
|
|
|
|
| | Virginia Tech – Blacksburg, Virginia, United States |
|
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
| | University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
